AI Article Synopsis
- Leishmaniasis is a disease caused by the Leishmania protozoan, prevalent in tropical and subtropical regions, leading to significant health issues.
- The search for effective and non-toxic treatments for Leishmaniasis continues, particularly in light of rising drug resistance.
- This article discusses new chemotherapy developments, focusing on rational drug design, natural products from microorganisms and plants, and immunity-based treatments as innovative solutions for managing the disease.
Article Abstract
Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until the current days, the search for substances with antileishmanial activity, without toxic effects, and able to overcome the emergence of drug resistant strains still remains as the current goal. This article reports the development of new chemotherapies through the rational design of new drugs, the use of products derived from microorganisms and plants, and treatments related to immunity as new alternatives for the chemotherapy of leishmaniasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00436-008-0943-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!